Stockscreener 앱 받기
39.48
1.39%
-0.555
시간 외 거래:
39.47
-0.005
-0.01%
Harrow Inc 주식(HROW)의 최신 뉴스
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy (NASDAQ:HROW) - Seeking Alpha
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow (NASDAQ:HROW) Stock Rating Lowered by Zacks Research - MarketBeat
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Harrow announces product updates - Nashville Post
Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition - Yahoo Finance
Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth - Sahm
Q2 2026 Harrow Inc Earnings Call Transcript - GuruFocus
A Look at Harrow Inc (HROW) After 3.2% Decline -- GF Value $44.5 - GuruFocus
HROW Looks 10.8% Undervalued on GF Value™ as Market Prices Growt - GuruFocus
HROW Reiterated by BTIG -- Price Target Maintained at $63 - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Dem - GuruFocus
Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... - Yahoo Finance
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Harrow Q2 2026 slides: strong demand growth amid profitability push By Investing.com - Investing.com Canada
Harrow Releases Q2 2026 Financial Results - AlphaStreet
Harrow Q2 Earnings Call Highlights - MarketBeat
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
Harrow Health, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harrow, Inc. (HROW) Q2 FY2026 earnings call transcript - Yahoo Finance
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline - TradingView
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story - simplywall.st
HROW Looks 8.5% Undervalued on GF Value™ - GuruFocus
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Harrow affirms FY26 sales guidance of $350-365M vs $348.468M est - scanx.trade
HROW Looks 8.5% Undervalued on GF Value™ Amid Mixed Growth Signa - GuruFocus
Harrow, Inc. Announces $17.3 Million Net Loss in Q2 2026 Amid Revenue Growth - Kalkine Media
Harrow: Q2 Earnings Snapshot - marketscreener.com
Is Harrow Inc (HROW) Positioned for Growth After Q2 Earnings Rep - GuruFocus
Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Harrow, Inc. Releases Q2 2026 Earnings and Corporate Update - Kalkine Media
Harrow Q2 Swings to Loss, Revenue Rises - marketscreener.com
Harrow, Inc. (HROW) stock falls on Q2 2026 Earnings - Quiver Quantitative
Harrow Q2 Results: EPS Misses Estimate, Sales Rise 10.85% YoY - scanx.trade
(HROW) Harrow Expects Full Year 2026 Revenue Range $350M$365M, vs. FactSet Est of $348.5M - marketscreener.com
Earnings Flash (HROW) Harrow Posts Q2 Loss $0.46, vs. FactSet Est of $0.18 Loss - marketscreener.com
Harrow, Inc. (HROW) grows branded eyecare sales as losses and debt increase - Stock Titan
HROW: Q2 revenue surged 60% sequentially, with robust product growth and guidance reaffirmed - TradingView
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, vs. FactSet Est of $70.4M - marketscreener.com
Harrow Announces Second Quarter 2026 Financial Results - The Manila Times
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M - Moomoo
BRIEF-Harrow Inc Q2 Gross Margin 71% - TradingView
Harrow, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback? By Investing.com - Investing.com UK
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback? - Investing.com
HARROW HEALTH Q2 2026 Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Harrow (HROW) After The Pullback, Is Its Growth Story Still Undervalued - simplywall.st
HROW Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow Inc: Expects to Fund Upfront Cash Paym - Moomoo
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook - TradingView
Form 8K Harrow Health Inc For: 6 August By Investing.com - Investing.com Nigeria
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M - Seeking Alpha
The only FDA-approved dry-eye nasal spray is set to join Harrow later in 2026 - Stock Titan
Harrow, Inc. (HROW) Stock Analysis: Exploring the 73% Upside Potential for This Eyecare Innovator - DirectorsTalk Interviews
Harrow (HROW) to Announce Earnings on Monday - MarketBeat
HROW Q2'26 Earnings: revenue estimate is 70.35M USD - tradingview.com
Harrow Inc. (HROW) Dips 0.44% to $38.77 as Shares Consolidate Between Support and ResistanceFund Manager Survey - dars.gov.et
Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing - Stock Titan
Principal Financial Group Inc. Takes $1.83 Million Position in Harrow, Inc. $HROW - MarketBeat
1.61%
1.30%
자본화:
|
볼륨(24시간):